Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:56:30.151Z.
Calculation as of: 2026-10-06T14:56:30.151Z.
Quote observation: 2026-10-06T14:55:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80308b770ced1bdfd1e00e86669fc95a739831df2c659c0b91f47c7a41a76c0c
PEG RATIO
N/A
Cue Biopharma, Inc.
Market Cap
$173.89M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Cue Biopharma, Inc. (CUE) | $173.89M | N/A |
| MediWound Ltd. (MDWD)vs › | $172.77M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.18M | N/A |
| Nkarta, Inc. (NKTX)vs › | $172.07M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $177.78M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $169.41M | N/A |
| Journey Medical Corporation (DERM)vs › | $179.09M | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $168.56M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.85M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $165.32M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
